Rifampicin Dexamethasone

NA /D, abd pain, bleeding, fevCT, T QT Interactions t Effects W7 atazanavir, clarithromycin, CT5rthromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfi-navir, ritonavir, saquinavir, telithromycin X effects W7 antacids, carbamazqjine, dexamethasone, phenobarbital, phenytoin, rifampicin, St. John s wort EMS Drug contains lactose, may cause D/abd discomfort in pts w/ lactose intolerance OD Sxs unknown symptomatic and supportive... 

Rifampicin and pregnenolone-16a-carbonitrile (PCN) induce members of the CYP3A family and represent a third type of inducer, in that the substrate specificity of the microsomes from treated animals differs from that of the microsomes from either phenobarbital-treated or TCDD-treated animals. Inducing substrates of this class include endogenous and synthetic glucocorticoids (e.g., dexamethasone), pregnane... 

ALMOTRIPTAN, ELETRIPTAN IMMUNOMODULATING DRUGS - CORTICOSTEROIDS-DEXAMETHASONE Possible 1 plasma concentrations of almotriptan and risk of inadequate therapeutic efficacy One of the major metabolizing enzymes of almotriptan - CYP3A4 isoenzymes - are induced by rifampicin. As there are alternative metabolic pathways, the effect may not be significant and can vary from individual to individual Be aware of possibility of 1 response to triptan, and consider t dose if considered to be due to interaction... 

IFOSFAMIDE 1. ANTIBIOTICS-rifampicin 2. ANTICANCER AND IMMUNOMODULATING DRUGS - dexamethasone 3. ANTIDEPRESSANTS-St John s wort 4. ANTI EPILEPTICS -carbamazepine, phenytoin, phenobarbital t rate of biotransformation to 4-hydroxyifbsfamide, the active metabolite, but there is no change in AUC of 4-hydroxyifosfamide Due to t rate of metabolism and of clearance owing to induction of CYP3A4 and CYP2D6 Be aware - clinical significance may be minimal or none... 

The efflux transporter P-glycoprotein (P-gp) has been proposed as a potential therapeutic target for AD [439]. Approximately 10-35 % decrease in 125I-Ap(i 0) intracellular accumulation was observed in cells treated with rifampicin, dexamethasone, caffeine, verapamil, hyperforin, p-estradiol, and pentylenetetrazole, drugs known to induce P-gp expression [439],... 

An improvement of medical devices based on bacterial polymers by the encapsulation of different drugs, opens up the wide prospects in applications for these new devices with pharmacological activity in medicine. PHB polymer was used as a drug delivery matrix for sustaining the release of various drugs such as dipyridamole [DP], indomethacin and antibiotics (rifampicin, metronidazole, ciprofloxacin, levofloxacin), anti-inflammatory drugs (flurbiprofen, dexamethasone, prednisolone), and antitumor drugs (paclitaxel) [132]. 

Enzyme inducers. The effects of the enzyme inducers carbamazepine, dexamethasone, phenytoin and rifampicin have not been studied with parecoxib. Nevertheless, the manufacturer of parecoxib warns that they may increase the metabolism of valdecoxib. ... 

As parecoxib is rapidly metabolised to valdecoxib, the interactions are usually considered to be due to the effects of valdecoxib. The manufacturer of parecoxib cautions the concurrent use with carbamazepine, dexamethasone and rifampicin as their effects on parecoxib have not been studied. Valdecoxib increases the levels of dextromethorphan and omeprazole. Because of these interactions, caution is advised with drugs that are metabolised by the same isoenzymes, nameiy flecainide, metoprolol, propafenone, omeprazoie, diazepam, imipramine and phenytoin. No interaction appears to occur between parecoxib and midazolam. 

The UK manufacturers point out that carbamazepine, dexamethasone, phenobarbital, phenytoin and rifampicin are all inducers of CYP3A4, an isoenzyme involved in the metabolism of sibutramine. These drugs might therefore increase the metabolism of sibutramine resulting in a fall in its serum levels. However, this has not been studied experimentally and, at the present time, the existence, the extent and the possible clinical relevance of any such interaction is unknown. 

Rifampicin modestly reduces the trough levels of caspofungin after 2 weeks of concurrent use, but this is not thought to be due to increased metabolism. One case of caspofungin treatment failure has been reported in a patient taking rifampicin. Other enzyme inducers (carbamazepine, dexamethasone, efavirenz, nevirapine, and phenytoin) also appeared to reduce caspofungin levels. Rifampicin and other unnamed enzyme inducers did not appear to alter anidulafungin clearance. 

---